Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mutiple myeloma

- PMLiVE

Eylea set to challenge Lucentis in UK after NICE recommendation

Bayer’s medicine recommended for NHS use to treat wet AMD

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Bayer wins EU approval for Xarelto in ACS

Comes despite US FDA decision not to recommend extra indication for anticoagulant

- PMLiVE

J&J expects to file 10 new pharma products by 2017

Healthcare company also expects 25 significant brand-line extensions

- PMLiVE

New chief information officer at Bayer Healthcare

Promotion for Johannes Schubmehl

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

- PMLiVE

France ignores EMA and suspends Bayer’s Diane 35

National Agency for the Safety of Drugs and Health Products contradicts PRAC verdict

Bayer symbol

EMA says Bayer’s Diane 35 should remain on European market

Agency investigation concludes acne treatment's benefits outweigh its risks

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

Bayer symbol

Bayer boosts consumer care business with Steigerwald purchase

Fuels ambition to become world leader in OTC medicines

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links